Expression of collagens in the damage area at abdominal adhesions

Abstract

Background. Postoperative adhesions are a serious problem in surgery. However, at the present time molecular
 mechanisms of the adhesion process are insufficiently studied.
 Aim. To study the dynamics of expression of genes encoding the synthesis of collagen in case of damage to the serosa
 on the example of the peritoneum in conditions of aseptic inflammation.
 Materials and methods. Aseptic inflammatory process in the abdominal cavity was modeled (Wistar rats, n = 40).
 A micro- and macroscopic picture of the damage area was studied. Immunofluorescent staining for Type I collagen
 (Col 1A1) was performed. The expression of genes encoding collagen of different types was evaluated using the RT 2 -
 Profiler PCR kit Array Rat Wound Healing.
 Results. It has been established that the adhesion process with peritoneal damage in aseptic conditions reaches its
 maximum by the 30 th day of observation. The same period coincides with the maximum of collagen synthesis in fibro-
 blasts in the repair area, revealed by immunofluorescence study. The interrelation of synthesis of type I and III collagens
 went as expected – the onset of expression of type III collagen (from day 3) is ahead of the expression of collagen type I
 (from day 7). Peak gene expression of collagens type I, Alpha-1 and -2; type III Alpha-1, type IV Alpha-1 and -3, type V
 Alpha-1, -2 and -3; type XIV Alpha-1 (Col14a1) falls on the 14th day. For the first time, active involvement of type V
 alpha-3 collagen in the adhesion process was noted - we detected both early (from day 1) and maximum intensive (up
 to 166.96 times increase in comparison with intact animals).
 Conclusion. Perhaps, the hyperexpression of collagen V alpha-3 that we revealed is an important link in the pathogenesis
 of adhesion in the abdominal cavity.

Using Ki-67 Mitotic Activity Markers as a Predictor of the Progression of Adhesions in the Abdominal Cavity

“…(28) The studies were carried out in two groups: Group 1 (control group, n=25) -modeling the adhesive process; Group 2 (experimental group, n=25) -modeling the adhesive process with administration of Seroguard® (conjugate the 4-[4-(4-fluorophenyl)-2-(4-methylsulfylphenyl)-1H-imidazole-5-pyridine with poly-1-vinylimidazole, JSC Pharmasyntez), 3 ml during the completion of the operation. (29) The animals were sacrificed on Days 1, 3, 7, 14, and 30. The severity of the adhesive process in AC was assessed using our own scale.…”